Library Item Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Evaluating the effectiveness and safety of pembrolizumab given after surgery in patients with stage II melanoma.

Evaluating the effectiveness and safety of pembrolizumab given after surgery in patients with stage II melanoma.

Posted by on Sep 30, 2022 in Melanoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) given after surgery in patients with stage II melanoma. The data showed that pembrolizumab given after surgery for up to 1 year significantly reduced the risk of cancer recurrence or death in these patients. Some background Melanoma is one of the most...

Read More

Comparing the effectiveness and safety of single-dose versus multiple-dose GnRH agonist for luteal-phase support in patients undergoing IVF/ICSI cycles.

Comparing the effectiveness and safety of single-dose versus multiple-dose GnRH agonist for luteal-phase support in patients undergoing IVF/ICSI cycles.

Posted by on Sep 29, 2022 in Infertility | 0 comments

In a nutshell This study compared the effectiveness and safety of single-dose (DS) versus multiple-dose (MD) GnRH agonist protocol for luteal phase support in patients undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles. The data showed that the MD protocol was more effective in increasing the live birth and...

Read More

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Evaluating the benefits of radiotherapy dose escalation and the addition of short-term or long-term androgen deprivation therapy in men with localized prostate cancer.

Posted by on Sep 27, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the benefits of radiation therapy (RT) dose escalation and the addition of short-term (ST) or long-term (LT) androgen deprivation therapy (ADT) to RT in men with localized prostate cancer (PCa). The data showed that the addition of ST or LT-ADT to RT improved survival without metastasis in these patients,...

Read More

Combining anti-CD19 CAR T-cell therapy with ibrutinib for treating chronic lymphocytic leukemia

Combining anti-CD19 CAR T-cell therapy with ibrutinib for treating chronic lymphocytic leukemia

Posted by on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to investigate if anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and ibrutinib (Imbruvica) could be combined for the treatment of patients with chronic lymphocytic leukemia (CLL).   This study concluded that adding anti-CD19 CAR T-cell therapy (CART-19) to ibrutinib treatment in these patients...

Read More

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

Comparing salvage intensive chemotherapy and venetoclax combined with low-intensity regimens in patients with relapsed/refractory acute myeloid leukemia

Posted by on Sep 27, 2022 in Leukemia | 0 comments

In a nutshell The study aimed to compare salvage intensive chemotherapy (IC) and a venetoclax (Venclexta; VEN)-combined low-intensity regimen in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML).   This study concluded that the VEN-combined regimen provided similar responses and survival rates when compared to...

Read More

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

Posted by on Sep 27, 2022 in Hodgkin's lymphoma | 0 comments

In a nutshell This study assessed the accuracy of whole-body (WB) magnetic resonance imaging (MRI) in evaluating the treatment response of blood cancers. The data indicated that WB-MRI had a high diagnostic performance for assessing the treatment response of blood cancers and its addition was strongly linked to better diagnostic...

Read More

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

Posted by on Sep 27, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the accuracy of whole-body (WB) magnetic resonance imaging (MRI) in evaluating the treatment response of blood cancers. The data indicated that WB-MRI had a high diagnostic performance for assessing the treatment response of blood cancers and its addition was strongly linked to better diagnostic sensitivity. Some...

Read More

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

How effective is whole-body MRI as an imaging technique for measuring treatment responses in patients with blood cancers?

Posted by on Sep 27, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study assessed the accuracy of whole-body (WB) magnetic resonance imaging (MRI) in evaluating the treatment response of blood cancers. The data indicated that WB-MRI had a high diagnostic performance for assessing the treatment response of blood cancers and its addition was strongly linked to better diagnostic sensitivity. Some...

Read More

Evaluating the long-term effects of non-pharmacological interventions on diabetes and chronic complication outcomes in patients with high blood glucose levels.

Evaluating the long-term effects of non-pharmacological interventions on diabetes and chronic complication outcomes in patients with high blood glucose levels.

Posted by on Sep 20, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the long-term effects of non-pharmacological (non-drug) interventions on diabetes and chronic complication outcomes in patients with high blood glucose (hyperglycemia) levels. The data showed that non-pharmacological interventions have a long-term effect on reducing diabetes occurrence among prediabetic patients...

Read More

Evaluating the long-term effectiveness and safety of injections under the skin of daratumumab versus intravenous infusions for patients with relapsed or refractory multiple myeloma.

Evaluating the long-term effectiveness and safety of injections under the skin of daratumumab versus intravenous infusions for patients with relapsed or refractory multiple myeloma.

Posted by on Sep 20, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study reported the final effectiveness and safety of subcutaneous (SC) injections versus intravenous (IV) infusions of daratumumab (Darzalex) in patients with relapsed or refractory multiple myeloma (MM). The data showed that daratumumab SC injections were as effective and caused fewer side effects than IV infusions over the long term...

Read More

Evaluating the effectiveness and safety of continuous subcutaneous night-time only apomorphine for the treatment of insomnia in patients with Parkinson’s disease.

Evaluating the effectiveness and safety of continuous subcutaneous night-time only apomorphine for the treatment of insomnia in patients with Parkinson’s disease.

Posted by on Sep 18, 2022 in Parkinson's Disease | 0 comments

In a nutshell This study evaluated the effectiveness and safety of continuous subcutaneous night-time only apomorphine (Apokyn) infusion for the treatment of insomnia in patients with Parkinson’s disease (PD). The data showed that continuous subcutaneous night-time only apomorphine was effective in improving sleep disturbances in patients with...

Read More

Evaluating the long-term effectiveness and safety of palbociclib plus fulvestrant treatment in patients with HR+/HER2- advanced BC.

Evaluating the long-term effectiveness and safety of palbociclib plus fulvestrant treatment in patients with HR+/HER2- advanced BC.

Posted by on Sep 18, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of palbociclib (Ibrance) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding palbociclib to fulvestrant was safe and significantly improved the overall survival over the...

Read More